u.s. asthma therapies markets growing penetration of combination drugs spur growth “the tremendous...
TRANSCRIPT
U.S. Asthma Therapies Markets
Growing Penetration of Combination Drugs Spur Growth
“The tremendous success of bronchodilator/-corticosteroid combination drugs will continue to drive growth in the asthma market, leaving single-
agent therapies with limited growth opportunities to exploit throughout the forecast period”
Pharmaceutical Biotech Analyst Team
Frost & Sullivan
• Growing Patient Penetration of Combination Drugs
• Growing Acceptance of Dry Powder Inhaler Delivery Systems
• Development of Innovative Pulmonary Delivery Systems
Industry Trends
Frost & Sullivan provides:
• Detailed insights into recent developments and trends
• Drivers, restraints, challenges, and strategic recommendations
• Analyst insights on ‘hot topics’ and emerging applications
in the U.S. Asthma Therapies Markets
• Market sizing and competitive analysis
• Market forecasts and market share analysis
• Pricing analysis
• Product, vendor and end user analysis
Key Features
• Coverage: The United States
• Proven methodology encompassing extensive primary and secondary data and research
• Focused information and strategies that cover business and technology issues
• Credible data and analysis highlighting industry dynamics
• Winning strategies to help you create precise business plans
What We Offer
Current Market Participants• Find out how you compare to the competition• Assess current and future drivers and restraints• Determine and exploit new market share opportunities
New Entrants • Analyze challenges associated with the industry• Calculate time scales for strategy implementation• Position yourself to capitalize on the market’s unmet needs
Investment Community• Analyze long-term strategies of companies in the asthma therapies
markets• Determine which participants will outperform the competition• Assess attractiveness of investing in the asthma therapies markets
Who Will Benefit?
Bronchodilators, subdivided into:
• Short-Acting Beta2 Agonists• Long-Acting Beta2 Agonists• Anticholinergics• Methylxanthines
Anti-Inflammatories, subdivided into:
• Inhaled Corticosteroids• Anti-Leukotrienes• Mediator-Release Inhibitors• Other Emerging Anti-Inflammatory Therapeutics
Bronchodilator/Corticosteroid Combinations
Other Emerging Asthma Therapies
What’s Included
Key Market Participants
3M PharmaceuticalsaaiPharmaAbbott LaboratoriesAlpharmaApotex Corp.AstraZeneca PharmaceuticalsAventis Pharmaceuticals, Inc.Boehringer IngelheimDey, Inc.Forest Laboratories, Inc.GlaxoSmithKline Impax LabsInspire PharmaceuticalsInwood Pharmaceuticals
Ivax Pharmaceuticals, Inc.King Pharmaceuticals, Inc.Merck & Co., Inc.Morton Grove PharmaceuticalsNovartis PharmaceuticalsPurdue PharmaceuticalsRoxane LaboratoriesSavage LaboratoriesSchering-PloughSepracor, Inc.Sheffield PharmaceuticalsTeva PharmaceuticalsUCB PharmaWallace PharmaceuticalsWarrick Pharmaceuticals
• Call toll free 877 GO FROST
(877.463.7876)
• Fax toll free 888.690.3329
• Email [email protected]
• Visit www.frost.com
For More Information